Treatment with an updated fixed-dose combination (FDC) of rifampicin/isoniazid/ pyrazinamide may decrease the risk for insufficient exposure to rifampicin among children with tuberculosis (TB) infection, according to results of a prospective study published in Clinical Infectious Diseases.